- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05438537
A Comprehensive Prospective Assessment of the Physical and Biological Effects of Upper Tract Urothelial Cancer (UTUC)
Study Overview
Status
Conditions
Detailed Description
Although Upper Tract Urothelial Carcinoma (UTUC) is relatively uncommon, the incidence rate is increasing. There are many controversies and limitations in the management of Upper Tract Urothelial cancer.
In this study, investigators would like to establish a local registry for upper tract urothelial cancer to facilitate the collection of clinical information and outcomes of upper tract urothelial cancer management, and to collect blood, urine and tumour tissue samples to investigate for new diagnostic and therapeutic agents. Hopefully, our registry can provide information regarding the epidemiology, natural history, and treatment outcomes of upper tract urothelial cancer in Hong Kong.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Jeremy Yuen-Chun TEOH, FRCS(Ed)
- Phone Number: 3505-2625
- Email: jeremyteoh@surgery.cuhk.edu.hk
Study Locations
-
-
-
Hong Kong, Hong Kong
- Recruiting
- Prince of Wales Hospital
-
Contact:
- Jeremy Yuen-Chun TEOH, FRCS(Ed)
- Phone Number: 35052625
- Email: jeremyteoh@surgery.cuhk.edu.hk
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Male patients > 18 years old
- Patients who has presence of UTUC and pending for surgery
- Patients who has history of UTUC with any intervention performed
Exclusion Criteria:
- Patients fail to provide informed consent
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Long-term survival
Time Frame: 10 years
|
Long-term survival
|
10 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recurrence rate of UTUC
Time Frame: 10 years
|
Recurrence rate of UTUC
|
10 years
|
Progression rate of UTUC
Time Frame: 10 years
|
Progression rate of UTUC
|
10 years
|
Complications
Time Frame: 10 years
|
Complications are assessed by medical record and on patient follow up
|
10 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jeremy Yuen-Chun TEOH, FRCS(Ed) MBBS, Chinese University of Hong Kong
Publications and helpful links
General Publications
- Munoz JJ, Ellison LM. Upper tract urothelial neoplasms: incidence and survival during the last 2 decades. J Urol. 2000 Nov;164(5):1523-5.
- Cauberg EC, Salomons MA, Kummerlin IP, de Reijke TM, Zwinderman AH, de la Rosette JJ, Kate FJ, Laguna Pes MP. Trends in epidemiology and treatment of upper urinary tract tumours in the Netherlands 1995-2005: an analysis of PALGA, the Dutch national histopathology registry. BJU Int. 2010 Apr;105(7):922-7. doi: 10.1111/j.1464-410X.2009.08889.x. Epub 2009 Oct 5.
- Lughezzani G, Burger M, Margulis V, Matin SF, Novara G, Roupret M, Shariat SF, Wood CG, Zigeuner R. Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature. Eur Urol. 2012 Jul;62(1):100-14. doi: 10.1016/j.eururo.2012.02.030. Epub 2012 Feb 23.
- Mellemgaard A, Carstensen B, Norgaard N, Knudsen JB, Olsen JH. Trends in the incidence of cancer of the kidney, pelvis, ureter and bladder in Denmark 1943-88. Scand J Urol Nephrol. 1993;27(3):327-32. doi: 10.3109/00365599309180442.
- Remzi M, Shariat S, Huebner W, Fajkovic H, Seitz C. Upper urinary tract urothelial carcinoma: what have we learned in the last 4 years? Ther Adv Urol. 2011 Apr;3(2):69-80. doi: 10.1177/1756287211403349.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- CRE 2020.484
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Upper Tract Urothelial Cancer
-
RenJi HospitalCompletedNeoadjuvant Immunotherapy of Cisplatin-ineligible High Risk Upper Urinary Tract Urothelial CarcinomaChina
-
The European Uro-Oncology GroupCentre for Human Drug Research, NetherlandsRecruitingUpper Tract Urothelial CarcinomaNorway, Spain, Netherlands
-
AnchorDx Medical Co., Ltd.Peking University First Hospital; Peking Union Medical College Hospital; Peking... and other collaboratorsRecruitingUpper Tract Urothelial CarcinomaChina
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingUpper Tract Urothelial CarcinomaUnited States
-
RenJi HospitalUnknown
-
Jinling Hospital, ChinaRecruitingCarcinoma | Upper Tract Urothelial Carcinoma | UTUCChina
-
Fox Chase Cancer CenterCompletedMuscle Invasive Bladder Cancer | High Risk Urothelial Carcinoma of the Upper Urinary TractsUnited States
-
YULISUOno Pharmaceutical Co. LtdRecruitingUpper Urinary Tract Urothelial CarcinomaTaiwan
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)CompletedHigh Grade Upper Tract Urothelial CarcinomaUnited States
-
Xiangya Hospital of Central South UniversityHunan Cancer Hospital; The Third Xiangya Hospital of Central South University; Hunan Provincial People's Hospital and other collaboratorsCompletedHigh-Grade Upper Tract Urothelial CarcinomaChina